Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Image source: Getty Images. Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per the terms of the agreement, Regeneron will ...

US drugmakers are betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

Is Regeneron stock a buy now? Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per the terms of the agreement, Regeneron will ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Regeneron Pharmaceuticals in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China’s Hansoh Pharmaceuticals 3692.HK. By licensing a drug in ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

Through the deal announced Monday, the Maryland-based company gets ex-China rights to SIM0505, an ADC developed by Simcere that targets CDH6 combined with a topoisomerase 1 inhibitor. NextCure will ...